Investing.com - Financial Markets Worldwide
🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Vivos Inc (RDGL)

OTC Markets
Currency in USD
Disclaimer
0.1745
+0.0050(+2.95%)
Closed
After Hours
0.1688-0.0057(-3.2665%)

RDGL Comments

Any body know why this hunk of junk is performing
my bank sold the stock on me hmmm I wonder why total set up
Have there been any other reports from the FDA???
There was news today you should check it out
Starting the run up to FDA IDE.  Boston Scientific's TheraSpheres product which is different but same radionuclide was used under IDE for almost 20 years.   A lot of money can be made in this space without having full FDA approval.  FDA IDE is the big step to start using in humans.  I expect a run back up to at least $0.36 leading up to FDA IDE.
Sorry about the multiple posts, they weren't showing up so I submitted a few times haha.
Currently holding 100k shares, the science behind this medical technology is sound (from a nuclear science standpoint), and I personally feel that the success of the pet version (Isopet) leads to a much more likely outcome that it will be a successful human treatment for cancerous, nonresectable (inoperable) tumors.
Currently holding 100k shares, the science behind this medical technology is sound (from a nuclear science standpoint), and I personally feel that the success of the pet version (Isopet) leads to a much more likely outcome that it will be a successful human treatment for cancerous, nonresectable (inoperable) tumors.
Currently holding 100k shares, the science behind this medical technology is sound (from a nuclear science standpoint), and I personally feel that the success of the pet version (Isopet) leads to a much more likely outcome that it will be a successful human treatment for cancerous, nonresectable (inoperable) tumors.
Hi! I would love to join in, but the company is so small that it's hard to gather news, info, data. Anyone? Thanks. Cheers!
Why don't you research the company online.  Tones of info.  Then decide.  Or stick with what you know.
bought 14000
🚀🚀🚀
PPS went up 44.03% today 🤑📈
On or before Jan 16 the FDA will approve or deny Radiogel for breakthrough designation. Radiogel is this companies product. Look it up.
So did they get the approval cant find anything on it.?
is this good stock to buy?
I think so. I bought some!
very good! I'm up 250% rn. expecting FDA approval news very soon!
"These guys have Facebook and Twitter pages. Go check them out! Great STORIES behind RDGL' 🐂🏃💨
Buy Buy Buy!!! going up to a $1 soon!
wouldnt that be nice been holding since 2018
RDGL closed @ 135% over yesterdays closing price
Pending FDA Approval Should know something before or on the day of January 16th 2021 🤑🤑🤑🤑🤑🤑
RDGL went up 158% today 🤑📈
Great PR today!
The last 3 post were from the article
***Same article***
Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (RDGL) (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet® into the equine market by making IsoPet® available to treat solid tumors in horses. The most common tumors are equoids and sarcomas. This is an important expansion of Vivos’ business plan.
Our  regional clinic in the state of Missouri for IsoPet® therapy has agreed to expand into IsoPet® therapy on solid tumors in horses. The initial few therapies will be subsidized, while we fine-tune the details of the treatment technique, but we are confident that IsoPet® will be the best option available to treat these tumors.
Dr. Mike Korenko stated, “Treating large tumors in large animal is a special challenge, but with our experience on large tumors in small animals we have the data necessary to proceed to this next step. This is a potentially lucrative market as Isopet® provides a highly differentiated treatment alternative for horses suffering with solid tumors
 LOSANGELES, CA / ACCESSWIRE / September 1, 2020 / Vivos Inc (RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals and in humans, today announced that it will be presenting at the LD 500 investor conference on Thursday September 3 at 1:40 PST / 4:00 PM EST. Dr. Mike Korenko (CEO of Vivos Inc) will be presenting to a live virtual audience.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.